BioMarin Pharmaceutical (BMRN) Received its Third Buy in a Row

After SVB Securities and Piper Sandler gave BioMarin Pharmaceutical (NASDAQ: BMRN) a Buy rating last month, the company received another Buy, this time from Wedbush. Analyst Liana Moussatos reiterated a Buy rating on BioMarin Pharmaceutical today and set a price target of $146.00. The company’s shares closed last Tuesday at $77.30.

According to TipRanks.com, Moussatos ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -13.4% and a 28.3% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics, Pacira Pharmaceuticals, and Liquidia Technologies.

BioMarin Pharmaceutical has an analyst consensus of Strong Buy, with a price target consensus of $115.69, implying a 43.8% upside from current levels. In a report released today, Piper Sandler also maintained a Buy rating on the stock with a $125.00 price target.

See the top stocks recommended by analysts >>

BioMarin Pharmaceutical’s market cap is currently $14.98B and has a P/E ratio of 462.69.

Based on the recent corporate insider activity of 65 insiders, corporate insider sentiment is neutral on the stock. Last month, George Eric Davis, the EVP, Chief Legal Officer of BMRN bought 2,669 shares for a total of $99,981.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline include Vosoritide (BMN 111) for Achondroplasia and Valoctocogene Roxaparvovec (BMN 270) for Hemophilia A. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.

Read More on BMRN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed